651 related articles for article (PubMed ID: 27996251)
21. Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(ii) carbazole-based hydrazone complexes.
Sathiya Kamatchi T; Mohamed Subarkhan MK; Ramesh R; Wang H; Małecki JG
Dalton Trans; 2020 Aug; 49(32):11385-11395. PubMed ID: 32776042
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
El-Adl K; El-Helby AA; Sakr H; Elwan A
Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, computational quantum chemical study, in silico ADMET and molecular docking analysis, in vitro biological evaluation of a novel sulfur heterocyclic thiophene derivative containing 1,2,3-triazole and pyridine moieties as a potential human topoisomerase IIα inhibiting anticancer agent.
Murugavel S; Ravikumar C; Jaabil G; Alagusundaram P
Comput Biol Chem; 2019 Apr; 79():73-82. PubMed ID: 30731361
[TBL] [Abstract][Full Text] [Related]
24. Strong Influence of Ancillary Ligands Containing Benzothiazole or Benzimidazole Rings on Cytotoxicity and Photoactivation of Ru(II) Arene Complexes.
Lari M; Martínez-Alonso M; Busto N; Manzano BR; Rodríguez AM; Acuña MI; Domínguez F; Albasanz JL; Leal JM; Espino G; García B
Inorg Chem; 2018 Nov; 57(22):14322-14336. PubMed ID: 30379535
[TBL] [Abstract][Full Text] [Related]
25. Investigating the anticancer potential of 4-phenylthiazole derived Ru(II) and Os(II) metalacycles.
Getreuer P; Marretta L; Toyoglu E; Dömötör O; Hejl M; Prado-Roller A; Cseh K; Legin AA; Jakupec MA; Barone G; Terenzi A; Keppler BK; Kandioller W
Dalton Trans; 2024 Mar; 53(12):5567-5579. PubMed ID: 38426897
[TBL] [Abstract][Full Text] [Related]
26. Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
Hanif M; Nazarov AA; Hartinger CG; Kandioller W; Jakupec MA; Arion VB; Dyson PJ; Keppler BK
Dalton Trans; 2010 Aug; 39(31):7345-52. PubMed ID: 20601976
[TBL] [Abstract][Full Text] [Related]
27. Reversible pH-Responsive Behavior of Ruthenium(II) Arene Complexes with Tethered Carboxylate.
Martínez-Peña F; Infante-Tadeo S; Habtemariam A; Pizarro AM
Inorg Chem; 2018 May; 57(9):5657-5668. PubMed ID: 29688005
[TBL] [Abstract][Full Text] [Related]
28. Ruthenium Complexes are pH-Activated Metallo Prodrugs (pHAMPs) with Light-Triggered Selective Toxicity Toward Cancer Cells.
Qu F; Park S; Martinez K; Gray JL; Thowfeik FS; Lundeen JA; Kuhn AE; Charboneau DJ; Gerlach DL; Lockart MM; Law JA; Jernigan KL; Chambers N; Zeller M; Piro NA; Kassel WS; Schmehl RH; Paul JJ; Merino EJ; Kim Y; Papish ET
Inorg Chem; 2017 Jul; 56(13):7519-7532. PubMed ID: 28636344
[TBL] [Abstract][Full Text] [Related]
29. New Class of Half-Sandwich Ruthenium(II) Arene Complexes Bearing the Water-Soluble CAP Ligand as an in Vitro Anticancer Agent.
Guerriero A; Oberhauser W; Riedel T; Peruzzini M; Dyson PJ; Gonsalvi L
Inorg Chem; 2017 May; 56(10):5514-5518. PubMed ID: 28443659
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q
Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxic Ruthenium(II) Complexes of Pyrazolylbenzimidazole Ligands That Inhibit VEGFR2 Phosphorylation.
Chakraborty A; Roy S; Chakraborty MP; Roy SS; Purkait K; Koley TS; Das R; Acharya M; Mukherjee A
Inorg Chem; 2021 Dec; 60(23):18379-18394. PubMed ID: 34780170
[TBL] [Abstract][Full Text] [Related]
32. From Catalysis to Cancer: Toward Structure-Activity Relationships for Benzimidazol-2-ylidene-Derived N-Heterocyclic-Carbene Complexes as Anticancer Agents.
Lam NYS; Truong D; Burmeister H; Babak MV; Holtkamp HU; Movassaghi S; Ayine-Tora DM; Zafar A; Kubanik M; Oehninger L; Söhnel T; Reynisson J; Jamieson SMF; Gaiddon C; Ott I; Hartinger CG
Inorg Chem; 2018 Nov; 57(22):14427-14434. PubMed ID: 30406647
[TBL] [Abstract][Full Text] [Related]
33. Half-sandwich ruthenium(ii) complexes containing N^N-chelated imino-pyridyl ligands that are selectively toxic to cancer cells.
Tian M; Li J; Zhang S; Guo L; He X; Kong D; Zhang H; Liu Z
Chem Commun (Camb); 2017 Nov; 53(95):12810-12813. PubMed ID: 29143019
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationships for osmium(II) arene phenylazopyridine anticancer complexes functionalised with alkoxy and glycolic substituents.
Needham RJ; Bridgewater HE; Romero-Canelón I; Habtemariam A; Clarkson GJ; Sadler PJ
J Inorg Biochem; 2020 Sep; 210():111154. PubMed ID: 32771772
[TBL] [Abstract][Full Text] [Related]
35. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
[TBL] [Abstract][Full Text] [Related]
36. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A.
Trávníček Z; Matiková-Mal'arová M; Novotná R; Vančo J; Stěpánková K; Suchý P
J Inorg Biochem; 2011 Jul; 105(7):937-48. PubMed ID: 21536006
[TBL] [Abstract][Full Text] [Related]
38. Water-soluble trithiolato-bridged dinuclear ruthenium(II) and osmium(II) arene complexes with bisphosphonate functionalized ligands as anticancer organometallics.
Riedl CA; Rosner A; Harringer S; Salomon P; Hejl M; Jakupec MA; Kandioller W; Keppler BK
J Inorg Biochem; 2021 Dec; 225():111618. PubMed ID: 34607124
[TBL] [Abstract][Full Text] [Related]
39. Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.
Meier-Menches SM; Gerner C; Berger W; Hartinger CG; Keppler BK
Chem Soc Rev; 2018 Feb; 47(3):909-928. PubMed ID: 29170783
[TBL] [Abstract][Full Text] [Related]
40. Cancer cell cytotoxicity of cyclometalated compounds obtained with osmium(II) complexes.
Boff B; Gaiddon C; Pfeffer M
Inorg Chem; 2013 Mar; 52(5):2705-15. PubMed ID: 23427955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
